Proove Biosciences Presents P.I.L.L. 2 Study at International Conference on Opioids

• 

"We believe genetic testing will dramatically improve patient care and cost efficiency within the market." - Brian Meshkin, CEO, Proove Biosciences

Irvine, CA and Annapolis Junction, MD (PRWEB) June 16, 2014

Proove Biosciences, a commercial and research leader in personalized medicine, presented the PILL 2 study at last week’s I nternational Conference on Opioids. The conference was presented by the Journal of Opioid Management and hosted by Harvard Medical School.

The PILL 2 study examined the prevalence of genetic variations in a population of chronic pain patients who were taking prescription opioids. Proove researchers found that there is in fact a greater prevalence of these genetic variations in the study group vs. the control population.

“We believe the PILL 2 study shows how genetics can play an important role in personalizing treatment for chronic pain,” stated Brian Meshkin, President of Proove Biosciences. “When physicians are armed with knowledge about their patient’s genetic profile, they are better able to assess how that patient will respond to certain medications and treatments.”

“This study was only a baseline metric providing a benchmark to direct our future research efforts. We are analyzing co-occurring disorders, evaluating additional SNPs, haplotypes and continuously developing new IRB approved prospective studies.”

The International Conference on Opioids explores emerging opioid research and initiatives aimed at improving patient care and reducing harm. This year’s conference assembled experts on opioid analgesics who shared real world knowledge on therapies, as well as insight and perspective on the future of opioids in medicine.

“Proove Biosciences was honored to be among the world’s brightest minds in opioid therapy, research, and policy,” Meshkin said. “We believe genetic testing will dramatically improve patient care and cost efficiency within the market.”

About Proove Biosciences

Our mission is to change the future of medicine by providing proof to improve healthcare decisions. We envision a future when clinicians will know how patients are likely to respond to medications before writing a prescription. We believe such knowledge can be provided by genetic testing: Using a simple cheek swab, Proove performs proprietary genetic tests in its CLIA-certified laboratory. Healthcare providers use the results to evaluate how their patients will metabolize medications, and to screen for the likelihood of medication misuse.

Founded in 2009 with offices in Southern California and the Baltimore-Washington metropolitan area, Proove Biosciences is the leader in genetics-related personalized pain medicine research with hundreds of clinical research sites across the U.S. For more information, please visit http://www.proovebio.com or call toll free 855-PROOVE-BIO (855-776-6832).

PDF Print